Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts
International Journal of Molecular Sciences · 10.02.2024 · 25 (4) · 2150
DOI: 10.3390/ijms25042150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.02.2024. Verfasst von Mathias Chea und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Hématologie Biologique, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, 31059 Toul…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire d'Hématologie Biologique, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, 31059 Toulouse, France.
- School of Medicine, Université Toulouse III Paul Sabatier, 31062 Toulouse, France.
ORCID-Profile: Mathias Chea, Lucie Rigolot, Alban Canali, Francois Vergez
Zitieren
APA
Chea, M., Rigolot, L., Canali, A., & Vergez, F. (2024). Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. International Journal of Molecular Sciences, 25(4), 2150. https://doi.org/10.3390/ijms25042150
Vancouver
Chea M, Rigolot L, Canali A, Vergez F. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. International Journal of Molecular Sciences. 2024;25(4):2150. doi:10.3390/ijms25042150
BibTeX
@article{Chea2024,
author = {Chea, Mathias and Rigolot, Lucie and Canali, Alban and Vergez, Francois},
title = {Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {4},
pages = {2150},
doi = {10.3390/ijms25042150}
}
EUVIMED